Finalreceptor antagonist and major thromboembolic and haemorrhagic complications
| P2Y12 receptor antagonist dosing | Number of patients (%) | Major thromboembolic complications (mRS ≥ 3) | PRU at time of complication (% with PRU >240) | Major haemorrhagic complications (mRS ≥ 3) | PRU at time of complication (% with PRU < 60) |
|---|---|---|---|---|---|
| Clopidogrel, 150 mg daily | 5 (8%) | 1 (20%) | 292 (100%) | 1 (20%) | 10 (100%) |
| Clopidogrel, 75 mg daily | 20 (30%) | 0 | n/a | 0 | n/a |
| Clopidogrel, 75 mg every-other-day (n = 4) or 75 mg every-third-day (n = 7) | 11 (17%) | 0 | n/a | 0 | n/a |
| Clopidogrel, 75 mg every-fourth-day | 2 (3%) | 0 | n/a | 1 (50%) | 58 (100%) |
| Clopidogrel, 75 mg every-Monday-and-Friday | 10 (15%) | 0 | n/a | 0 | n/a |
| Clopidogrel, 75 mg every-fifth-day (n = 5) or 75 mg once-a-week (n = 3) | 8 (12%) | 0 | n/a | 0 | n/a |
| Clopidogrel suspension, 7.5 mg daily: | 1 (1.5%) | 0 | n/a | 0 | n/a |
| Prasugrel, 5 mg daily (n = 5) or 10mg daily (n = 3) | 8 (12%) | 0 | n/a | 2 (25%) | 0, 185 (50%) |
| Ticagrelor, 90 mg twice-a-day | 1 (1.5%) | 0 | n/a | 0 | n/a |